Corvus Pharmaceuticals Inc (CRVS) Holdings Lifted by Bridgeway Capital Management Inc.
Bridgeway Capital Management Inc. boosted its holdings in Corvus Pharmaceuticals Inc (NASDAQ:CRVS) by 23.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 104,600 shares of the company’s stock after purchasing an additional 19,600 shares during the quarter. Bridgeway Capital Management Inc. owned approximately 0.36% of Corvus Pharmaceuticals worth $897,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. Trexquant Investment LP bought a new position in Corvus Pharmaceuticals in the 3rd quarter worth approximately $107,000. Rhumbline Advisers bought a new position in Corvus Pharmaceuticals in the 2nd quarter worth approximately $147,000. Acadian Asset Management LLC boosted its stake in Corvus Pharmaceuticals by 129.3% in the 2nd quarter. Acadian Asset Management LLC now owns 21,494 shares of the company’s stock worth $236,000 after purchasing an additional 12,119 shares during the period. Credit Suisse AG bought a new position in Corvus Pharmaceuticals in the 3rd quarter worth approximately $194,000. Finally, Schwab Charles Investment Management Inc. boosted its stake in Corvus Pharmaceuticals by 48.0% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 25,900 shares of the company’s stock worth $285,000 after purchasing an additional 8,400 shares during the period. Institutional investors and hedge funds own 87.42% of the company’s stock.
CRVS has been the topic of several recent research reports. Cowen reaffirmed a “buy” rating on shares of Corvus Pharmaceuticals in a report on Friday, November 2nd. Credit Suisse Group raised Corvus Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $11.00 to $15.00 in a report on Wednesday, August 15th. BidaskClub raised Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, September 1st. Finally, Zacks Investment Research cut Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $13.58.
Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings data on Thursday, November 1st. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.12. On average, research analysts anticipate that Corvus Pharmaceuticals Inc will post -1.77 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://theolympiareport.com/2018/12/07/corvus-pharmaceuticals-inc-crvs-holdings-lifted-by-bridgeway-capital-management-inc.html.
Corvus Pharmaceuticals Profile
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.
Further Reading: Outstanding Shares and The Effect on Share Price
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.